• Prescribing Information
  • Patient Information
  • Patient Site
  • Medical Information
  • Vyndamax logo

    Resources

    Professional Resources Patient Resources Expert Videos

    VYNDAMAX and access physician resources

    VYNDAMAX Branded Brochure

    Brochure containing information about ATTR-CM and comprehensive clinical information about VYNDAMAX treatment.

    View Full Prescribing Information

    Download

    VYNDAMAX Flashcard

    A brief front-and-back flashcard about ATTR-CM diagnosis and VYNDAMAX treatment.

    View Full Prescribing Information

    Download

    VYNDAMAX Hereditary V122I Brochure

    Brochure that discusses the characteristics of the hereditary V122I mutation that can cause ATTR-CM in African American patients and is the most common hereditary mutation found in the US.

    View Full Prescribing Information

    Download

    VYNDAMAX Hereditary V122I Patient Profile

    A branded VYNDAMAX resource featuring a hypothetical hATTR-CM v122i patient profile. This resource can help educate Cardiologists to suspect hATTR-CM in their African American patients and also promotes appropriate use of VYNDAMAX for this patient population for which ATTR-CM is believed to be especially underdiagnosed.

    View Full Prescribing Information

    Download

    VyndaLink HCP Brochure

    A comprehensive overview of the VyndaLink program with information about office services and resources available.

    View Full Prescribing Information

    Download

    Patient Access Brochure

    A checklist designed to help guide you and your staff through the insurance process.

    View Full Prescribing Information

    Download

    CoverMyMeds® Brochure

    A review of the CoverMyMeds® Program to streamline the prior authorization process.

    View Full Prescribing Information

    Download

    Next: Patient resources

    Continue

    Savings & Support

    • Access & Patient Support
    • Resources

    Efficacy and safety outcomes

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Review the clinical data

    ** This is an optional area where footnotes can live.

    Connect patients to support through VyndaLink

    Explore access and patient support

    ** This is an optional area where footnotes can live.


    VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.

    Adverse Reactions

    In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

    Specific Populations

    Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

    Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

    VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
    ​​​​​​​
    Please see Full Prescribing Information including Patient Information.

      INDICATION AND LIMITATIONS OF USE

      VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
      ​​​​​​​
      Please see Full Prescribing Information including Patient Information.